Developing Antibody Drug Conjugate (ADC) therapeutics? Inotiv has mass spectrometry assays to quantify your ADC target protein in any sample type, including FFPE tissue, without antibodies. We have developed assays to 27 ADC targets for oncology and other therapeutic applications.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
April 7-11, 2025 New Orleans, LA Booth #41 Each year WRIB program provides you with novel case studies and emerging approaches because it is the only program built on White Paper r...
April 10-11, 2025 Gaithersburg, MD In-person Join Inotiv’s experts for a complimentary, educational workshop to gain in-depth knowledge of Genetic Toxicology.
April 25-30, 2025 Chicago, IL Booth #2509 The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and preventio...
December 30, 2024 WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization...
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
General Toxicology
Histology
Pathology
DMPK
Consulting
Research Models
Research Model Services
Teklad Diet and Bedding
